{"id":48100,"date":"2022-09-08T12:02:47","date_gmt":"2022-09-08T10:02:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/25-billion-antifungal-drugs-markets-2030-by-drug-class-infection-type-therapeutic-indications-dosage-forms-researchandmarkets-com\/"},"modified":"2022-09-08T12:02:47","modified_gmt":"2022-09-08T10:02:47","slug":"25-billion-antifungal-drugs-markets-2030-by-drug-class-infection-type-therapeutic-indications-dosage-forms-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/25-billion-antifungal-drugs-markets-2030-by-drug-class-infection-type-therapeutic-indications-dosage-forms-researchandmarkets-com\/","title":{"rendered":"$25+ Billion Antifungal Drugs Markets, 2030 by Drug Class, Infection Type, Therapeutic Indications, Dosage Forms – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030.\n<\/p>\n

\nGrowth of the anti-fungal drugs market is majorly driven by alarming rise in prevalence of chronic diseases such as diabetes and tuberculosis drives the growth of the market. In addition, growth in incidence of the prevalence rate of infectious diseases and growth in population of immuno-compromised (prone to infectious diseases) individuals contribute toward the growth of the market.\n<\/p>\n

\nFurthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period. Moreover, as per Centers for Disease Control and Prevention (CDC) estimates, there are roughly 46,000 cases of hospital-associated invasive candidiasis each year, a number that is increasing over the past two decades.\n<\/p>\n

\nHospital-associated invasive candidiasis is among the most common bloodstream infections found in hospitalized patients, and is caused by Candida yeasts that generally dwell in the gut and on the skin with some problems. This disease has led to death in about 30% of patients with bloodstream infections.\n<\/p>\n

\nMost cases of candidiasis fungal infection occur in the U.S. and Canada. In states where blastomycosis is reportable, yearly incidence rates are approximately 1 to 2 cases per 100,000 people. In addition, surge in healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs are the factors that propel the market growth. Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.\n<\/p>\n

\nThe antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region. By drug type, it is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. By therapeutic indication, it is classified into aspergillosis, dermatophytosis, candidiasis, and others. By infection type, the market is bifurcated into superficial and systemic antifungals.\n<\/p>\n

\nNorth America accounted for the highest market share in 2020, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals.\n<\/p>\n

\nHowever, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.\n<\/p>\n

\nSome of the major companies that operate in the global anti-fungal drugs market are Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Merck & Co. Inc, Novaris AG, Abbott Laboratories, GlaxosithKlinePlc, AstellasPharma Inc., Johnson & Johnson and Merz Pharma.\n<\/p>\n

\nKey Benefits For Stakeholders<\/strong>\n<\/p>\n